@kdhunt93's GLP-1 weight loss claims, fact-checked

What did @kdhunt93 actually say?

Honestly, the transcript here is a song playing in the background, not the creator speaking. The real content lives in the caption: a 29-pound loss (187 to 158), 13 pounds from goal, and an enthusiastic endorsement of GLP-1 therapy through ShedRx. "Best decision I ever made" is the core claim, paired with "DO IT" as direct advice to followers considering starting a GLP-1.

Worth being clear about what this video is and isn't. It's a progress update with a paid or affiliate promotion (discount code in bio), not a medical explainer. The creator isn't making pharmacological claims. They're sharing a personal result and recommending a platform. That context matters for how we evaluate what follows.

Does the science back this up?

A 29-pound loss is a plausible, real-world result for GLP-1 therapy, and the broader research supports that kind of outcome for many patients. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced mean weight loss of about 14.9% of body weight over 68 weeks. For a 187-pound starting weight, that math lands close to what this creator describes.

Tirzepatide data is even more striking. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% mean weight loss at the highest dose. So yes, results in this range are documented, reproducible, and not cherry-picked. The "DO IT" enthusiasm is understandable from a patient who's seeing results. The science does support meaningful weight loss for a significant portion of GLP-1 users, not everyone, but a large enough share that dismissing these drugs as hype is no longer credible.

What did they get wrong (or right)?

The creator got the personal result right, assuming the numbers are accurate, and GLP-1s are genuinely effective tools for weight management. Credit where it's due. But "DO IT" as blanket advice to 100,000 viewers is where this gets medically sloppy.

GLP-1 receptor agonists aren't appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pancreatitis history. Side effects, particularly nausea, vomiting, and gastrointestinal distress, lead a meaningful number of patients to discontinue. A 2023 real-world analysis by Wilkinson et al. in Obesity found discontinuation rates around 40-50% within a year in some patient populations.

The ShedRx promotion also warrants scrutiny. ShedRx and similar platforms typically prescribe compounded semaglutide or tirzepatide. Compounded versions are not FDA-approved and are not equivalent to brand-name Wegovy or Zepbound. Assuming they are is a mistake patients make regularly.

What should you actually know?

GLP-1 therapy can produce substantial, clinically meaningful weight loss, and that's not spin. The data is strong. But individual results vary considerably based on drug, dose, adherence, diet, and metabolic factors. One person's 29 pounds is not a guaranteed outcome.

If you're considering a telehealth GLP-1 platform after seeing content like this, a few things matter:

• Confirm whether you'd be prescribed FDA-approved branded medication or compounded alternatives. These are legally and clinically distinct products.
• Check that a licensed prescriber reviews your medical history before prescribing, not just a short intake form.
• Understand that weight often returns when medication is stopped. Long-term data from the STEP 4 trial (Rubino et al., 2021, JAMA) showed significant weight regain after semaglutide discontinuation.
• GLP-1s are not a permanent fix without behavioral change. They're a tool, and a good one, but not a standalone solution for most people.

The creator's experience is real and valid. Translating one person's success into universal advice is where things go sideways.